Constellation Pharmaceuticals to Host Conference Call to Discuss Fourth Quarter 2020 Results

Rhea-AI Summary

Constellation Pharmaceuticals will host a conference call on February 24, 2021, at 8:00 AM EDT, to discuss its fourth quarter 2020 results and provide a business update. The event will be accessible via live webcast on the company's website. Interested participants can join the Q&A session by calling (877) 473-2077 (domestic) or (661) 378-9662 (international), using conference ID 6971724. Constellation focuses on developing novel therapeutics for cancer, including the BET inhibitor pelabresib and EZH2 inhibitor CPI-0209.

CAMBRIDGE, Mass., Feb. 18, 2021 (GLOBE NEWSWIRE) -- Constellation Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company using its expertise in epigenetics to discover and develop novel therapeutics, will host a conference call at 8:00 AM EDT on February 24, 2021, to discuss its fourth quarter 2020 results and provide a business update. The event will be webcast live and can be accessed on the Investor Relations section of Constellation’s website at http://ir.constellationpharma.com/events-and-presentations/events. To participate in the live question-and-answer session, please dial (877) 473-2077 (domestic) or (661) 378-9662 (international) and refer to conference ID 6971724.

About Constellation Pharmaceuticals

Constellation Pharmaceuticals is a clinical-stage biopharmaceutical company developing novel therapeutics that selectively modulate gene expression to address serious unmet medical needs in patients with cancer. The Company has a deep understanding of how epigenetic and chromatin modifications in cancer cells and in the tumor and immune microenvironment play a fundamental role in driving disease progression and drug resistance. Constellation is driving development of the BET inhibitor pelabresib (CPI-0610) for the treatment of myelofibrosis as well as its EZH2 inhibitor CPI-0209 for the treatment of other cancers. The Company is also applying its broad research and development capabilities to explore other novel targets that directly and indirectly impact gene expression to fuel a sustainable pipeline of innovative small-molecule product candidates.

Contacts

Kia Khaleghpour, PhD
Vice President, Investor Relations and Communications
Constellation Pharmaceuticals
+1 617-844-6859
kia.khaleghpour@constellationpharma.com

Lauren Arnold
Media Relations
MacDougall Biomedical Communications
+1 781-235-3060
larnold@macbiocom.com

FAQ

What is the conference call date for Constellation Pharmaceuticals' fourth quarter results?

The conference call for Constellation Pharmaceuticals' fourth quarter results is on February 24, 2021.

What time will Constellation Pharmaceuticals' conference call begin?

The conference call will begin at 8:00 AM EDT.

How can I access the conference call for Constellation Pharmaceuticals?

You can access the conference call via live webcast on Constellation Pharmaceuticals' Investor Relations website.

What is the conference ID for the Q&A session at Constellation Pharmaceuticals' call?

The conference ID for the Q&A session is 6971724.

What are the contact numbers for Constellation Pharmaceuticals' conference call?

The domestic contact number is (877) 473-2077 and the international number is (661) 378-9662.